[Skip to Navigation]
Comment & Response
March 12, 2020

Notice of Retraction and Replacement. Kang et al. Association of statin use and high serum cholesterol levels with risk of primary open-angle glaucoma. JAMA Ophthalmol. 2019;137(7):756-765

Author Affiliations
  • 1Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
  • 2Department of Ophthalmology, Harvard Medical School, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts
  • 3Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor
  • 4Center for Eye Policy and Innovation, University of Michigan, Ann Arbor
  • 5Department of Health Management and Policy, University of Michigan School of Public Health, Ann Arbor
  • 6National Institute for Health Research Biomedical Research Centre, Moorfields Eye Hospital National Health Service Foundation Trust, University College London Institute of Ophthalmology, London, United Kingdom
  • 7Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts
  • 8now with Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, New York
JAMA Ophthalmol. 2020;138(5):588-589. doi:10.1001/jamaophthalmol.2020.0027

To the Editor We write to explain errors that occurred in our Original Investigation “Association of Statin Use and High Serum Cholesterol Levels With Risk of Primary Open-Angle Glaucoma,”1 published online on May 2, 2019, and in the July 2019 issue of JAMA Ophthalmology. In the original article, we reported that statin use of 5 or more years was associated with a lower risk of primary open-angle glaucoma (POAG) and that every 20-mg/dL increase in total serum cholesterol was associated with an increased risk of POAG. However, because of errors in our analyses, these findings are not accurate.

Add or change institution